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The human flavoenzyme D-amino acid oxidase (hDAAO) degrades the
NMDA-receptor modulator D-serine in the brain. Although hDAAO has
been extensively characterized, little is known about its main modulator
pLG72, a small protein encoded by the primate-specific gene G72 that has
been associated with schizophrenia susceptibility. pLG72 interacts with
neosynthesized hDAAO, promoting its inactivation and degradation. In
this work, we used low-resolution techniques to characterize the surface
topology of the hDAAO–pLG72 complex. By using limited proteolysis
coupled to mass spectrometry, we could map the exposed regions in the
two proteins after complex formation and highlighted an increased sensitiv-
ity to proteolysis of hDAAO in complex with pLG72. Cross-linking experi-
ments by using bis(sulfosuccinimidyl)suberate identified the single covalent
bond between T182 in hDAAO and K62 in pLG72. In order to validate
the designed mode of interaction, three pLG72 variants incrementally trun-
cated at the C terminus, in addition to a form lacking the 71 N-terminal
residues, were produced. All variants were dimeric, folded, and interacted
with hDAAO. The strongest decrease in affinity for hDAAO (as well as
for the hydrophobic drug chlorpromazine) was apparent for the N-terminally
deleted pLG7272–153 form, which lacked K62. On the other hand, eliminat-
ing the disordered C-terminal tail yielded a more stable pLG72 protein,
improved the binding to hDAAO, although giving lower enzyme inhibi-
tion. Elucidation of the mode of hDAAO–pLG72 interaction now makes it
possible to design novel molecules that, by targeting the protein complex,
can be therapeutically advantageous for diseases related to impairment in
D-serine metabolism.
Abbreviations
BS3, bis(sulfosuccinimidyl)suberate; CPZ, chlorpromazine; DAAO, D-amino acid oxidase; DTT, dithiothreitol; FAD, flavin adenine dinucleotide;
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Introduction
D-Amino acid oxidase (DAAO, EC 1.4.3.3) is a peroxi-
somal, homodimeric flavoenzyme displaying the prop-
erties of the dehydrogenase-oxidase class of
flavoproteins. It catalyzes the oxidative deamination of
D-amino acids into the corresponding a-keto acids
with the concomitant production of ammonia and
hydrogen peroxide [1,2]. In the brain, DAAO modu-
lates the concentration of D-serine, an allosteric coacti-
vator of the NMDA type of glutamate receptors
(NMDAR), which is mainly produced in neurons
through the racemization reaction catalyzed by the
enzyme serine racemase [3,4] and is released by neu-
rons and astrocytes [5]. Through the action on
NMDAR, the D-serine signaling system plays a key
role in developing brain wiring and regulating higher
brain functions, including cognitive, emotional, and
sensorimotor function [6]. On the other hand, aberrant
D-serine-dependent NMDAR activation is involved in
a variety of neurological diseases: excessive produc-
tion/release of D-serine is implicated in acute and
chronic degenerative disorders while abnormally low
levels have been observed in patients affected by psy-
chiatric disorders such as schizophrenia or bipolar dis-
orders [7–11]. In light of these findings, it was assumed
that a possible imbalance in the levels or activities of
the enzymes involved in D-serine metabolism might be
involved in the onset of such diseases.
We recently demonstrated that the function of
human DAAO (hDAAO) is regulated by the interact-
ing protein pLG72: its binding modifies tertiary struc-
ture and causes a time-dependent loss of activity of
the flavoenzyme, and thus modulates cellular D-serine
levels [12–15]. Notably, the G72 gene encoding for
pLG72 is among the most frequently replicated vulner-
ability genes for schizophrenia and bipolar disorder;
for a comprehensive review, see [16,17]. Several genetic
studies also found significant evidence for an associa-
tion between single nucleotide polymorphisms in the
DAAO gene and schizophrenia [18], although this con-
clusion is widely debated. pLG72 is a 153-amino acid
protein [19] with no recognizable functional motifs;
hence, it is valuable for investigating the structural
details of its interaction with hDAAO in order to shed
light on the molecular mechanisms by which pLG72
finely tunes D-serine levels by modulating flavoenzyme
activity. However, characterization of the protein com-
plex by high-resolution techniques constitutes an extre-
mely challenging task as: (a) structural information
about pLG72 is lacking, (b) pLG72 is soluble in the
presence of mild denaturants only [13,20], and (c)
no homologous protein has been structurally
characterized so far. For this reason, we decided to
employ low-resolution strategies, such as those based
on the coupling of classical biochemical approaches
(limited proteolysis and chemical cross-linking) with
the analytical power of mass spectrometric techniques.
Actually, by using different proteases and picking only
primary cleavage sites, i.e., those occurring on the
intact and native structure, it is possible to get a
detailed picture of the exposed protein backbone and
to compare the different conformations occurring
upon formation of complexes with molecular effectors
[21–23]. Furthermore, a cross-linking strategy can cap-
ture interactions between flexible regions of proteins in
solution by covalently linking amino acid side chains,
thus providing information on the regions involved in
protein–protein interfaces [24,25].
By using this approach, we characterized the surface
topology of the hDAAO–pLG72 complex and defined
the conformational changes induced in hDAAO by
pLG72 binding. Based on this information, we per-
formed molecular modeling of the pLG72 tertiary
structure coupled to hDAAO docking simulations.
Finally, deletion variants of pLG72 were prepared to
evaluate the inferred mode of interaction. Taken
together, this analysis sheds light on the hDAAO–
pLG72 complex, opening up the opportunity to design
molecules aimed to modulate the cellular concentration
of D-serine by acting on the stability/activity of
hDAAO through pLG72 binding.
Results
Limited proteolysis studies
In the assumption that the distribution of the preferen-
tial proteolytic sites is strictly dependent on the protein
conformation, limited proteolysis experiments, causing
single cleavage events in the protein structure (primary
site) and originating complementary peptide fragments
(‘complementary proteolysis’), seems well suited to
investigate conformational changes in protein structure
upon formation of protein complexes [21–23,26]. Based
on this approach, very few primary, complementary
cleavage sites are detected for highly structured pro-
teins that remain largely undigested, thus providing an
instrumental, low-resolution picture of the protein
topology. Limited proteolysis experiments have been
therefore designed to study the surface topology of
hDAAO–pLG72 complex on the grounds that the por-
tions of the protein involved in highly structured
regions are located at the intersubunits interface and
are thus protected from proteases. Enzymatic hydroly-
sis was carried out on the single proteins as well as on
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the hDAAO–pLG72 complex, incubating with pro-
teases at different enzyme-to-substrate (w/w) ratios,
investigating the time course of fragment formation by
RP-HPLC, and determining the mass by ESI-MS anal-
ysis.
Upon endoprotease Glu-C treatment of hDAAO,
only one primary cleavage site was detected, as only
two fragments that are ‘complementary’ were identi-
fied: peptides 1–249 and 250–347 (cleavage at E249).
Similar limited proteolysis experiments were carried
out using subtilisin and chymotrypsin: these proteases
cleaved at E249 and at the L189, L194, and L250 sites,
respectively (see Table 1). Digestion with trypsin
deserves some discussion: it produced a mixture of
undigested protein (residues 1–347) and the peptide 1–
341 (experimental mass value 38811.6  1.7 Da, theo-
retical mass value 38811.2 Da), indicating that
hDAAO is quickly cleaved at R341 and the C-terminal
hexapeptide is removed. The high degree of flexibility
and accessibility of the C-terminal region deduced
from these data is consistent with its absence in the
three-dimensional structure of the protein determined
by X-ray analysis [27]. Therefore, in the experiments
with trypsin, the truncated form 1–341 was considered
as the basic hDAAO molecule on which subsequent
hydrolysis occurred yielding peptides 1–191 and 192–
341, and indicating that a cleavage site was present at
Arg191.
The same experimental strategy was used for
pLG72: notably, the optimal enzyme-to-substrate ratio
was significantly lower than that used for hDAAO, as
could be expected by the inferred high flexibility of
pLG72 [20]. With the only exception of cleavage at site
W61 by chymotrypsin, all the proteases we used acted
on residues belonging to the C-terminal part of this
small protein (Table 1). Although the complementary
peptides in the digestion of pLG72 with endoprotease
Glu-C (Glu-C) and subtilisin were not detected, we
can still consider E146 and T150 as primary sites as
the cleavages occur at the very C-terminal end of the
protein, producing small complementary peptides (en-
compassing seven and three residues in Glu-C and
subtilisin digestion of pLG72, respectively) that are
then likely promptly digested. In case they were not
the actual primary cleavage site, the shift of a couple
of positions (unlikely because no fragment closer to
the C terminus was detected) does not change dramati-
cally the low-resolution picture of the superficial topol-
ogy of the protein.
In order to ensure that all the molecules of the
flavoenzyme were complexed with pLG72, experiments
on the hDAAO–pLG72 complex were carried out
using a fivefold molar excess of pLG72 protein (by
mixing 4 nmol hDAAO and 20 nmol of pLG72); com-
plex formation was confirmed by native gel analysis
(not shown). The large excess of pLG72 hampered to
deduce any structural information about the pLG72
regions involved in the complex because most of the
pLG72 molecules were not complexed with hDAAO.
As far as hDAAO is concerned, ESI/MS analyses
identified several complementary peptides with the dif-
ferent proteases (Table 1). Only for Glu-C digestion,
the complementary peptide was not detected and, anal-
ogously to that described above for pLG72 digestion
with Glu-C and subtilisin, we can consider E336 as a
primary site of proteolysis, as the complementary pep-
tide is relatively small (11 residues). Figure 1 shows
the position of the corresponding cleavage sites (lo-
cated at F167 and N180) as well as the sites recognized
by trypsin (R297), chymotrypsin (Y35, Y55, and
L296), and Glu-C (E336). Interestingly, all of them dif-
fer from those observed with the same proteases on
hDAAO in the absence of pLG72.
Based on these results, several conclusions can be
drawn: (a) hDAAO appears more accessible to pro-
teases in the pLG72-complexed form than as a single
protein (a lower enzyme-to-substrate ratio provides
optimal digestion of hDAAO in complex with
pLG72); and (b) a main conformational change is
induced in the hDAAO molecule by forming the com-
plex with pLG72, as deduced by the different patterns
of preferential proteolytic sites observed for hDAAO
in the presence and in the absence of pLG72. Specifi-
cally, the peptide bonds following L189, R191, L194
E249, and L250 that were proteolytically hydrolyzed
in the isolated hDAAO were not recognized in the
presence of pLG72: in contrast, the Y34, Y55, F167,
N180, L296, R297, and E336 sites were recognized in
the hDAAO–pLG72 complex only (Fig. 1).
Chemical cross-linking
Cross-links formed between residues of a protein or
proteins within a complex can be used as ‘molecular
rulers’ to determine short-distance molecular modeling
constraints which allow to elucidate the structures of
individual proteins, protein conformational changes,
or to provide insights into protein–protein interfaces.
We used the homobifunctional cross-linker bis(sulfos-
uccinimidyl)suberate (BS3), a cross-linker that prefer-
entially targets not only primary amino groups of
lysine side chains and the protein N termini but also
hydroxyl groups of serine and threonine side chains
[28,29], in the study of the hDAAO–pLG72 complex,
following the general strategy outlined in Fig. 2.
hDAAO (12.5 lM) and pLG72 (62.5 lM) were mixed
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(at 1 : 5 subunit molar ratio) and incubated for
15 min and then cross-linked by adding 50-fold molar
excess of BS3 (with respect to hDAAO monomers and
under optimized conditions). Electrophoretic and
immunodetection analysis of the reaction mixture
revealed the presence of a band at ~ 75 kDa positive
to both anti-hDAAO and anti-pLG72 antibodies
(Fig. 2), thus suggesting a covalent hDAAO–pLG72
complex formation following BS3 treatment.
In order to identify the cross-linking sites, a gel-free
strategy was adopted: the reaction mixture was
desalted, carboxyamidomethylated, trypsin digested,
and analyzed by LC-MSMS. In order to search for
species of low abundance, such as those expected from
cross-linked peptides, an exclusion list of signals aris-
ing from linear trypsin-digested peptides from the sin-
gle proteins was set up and inserted in the LC-MSMS
program, and the open mass modification strategy
developed by [30], based on Batch-Tag, MS-Bridge,
and MS-Product tools within the PROTEIN PROSPECTOR
package (http://prospector.ucsf.edu/prospector, Uni-
versity of California, San Francisco, CA, USA), was
used. Table 2 reports the peptides modified upon treat-
ment with BS3 in the hDAAO–pLG72 complex. All
putative cross-linkings were verified by manual inspec-
tion of the corresponding MS/MS spectrum. One
Protease (protease/
substrate ratio, w/w)
Identified
peptide
Experimental
mass value (Da)a
Theoretical
mass value (Da)
Proteolytic
site
hDAAO
Glu-C (1/500) 1–249 28280.49  1.69 28280.49 E249
250–347 11211.94  1.03 11211.90
Subtilisin (1/500) 1–189 21478.68  1.22 21478.33 L189
190–347 18041.14  0.59 18013.66
Trypsin (1/100) 1–341 38811.56  1.70 38811.16 R341
1–191 21763.63  1.46 21762.60 R191
192–341 17066.90  1.00 17066.50
Chymotrypsin (1/100) 1–250 28392.60  1.75 28393.20 L250
251–347 11098.27  0.37 11098.70
1–194 22089.81  1.99 22088.01 L194
195–347 17404.48  1.75 17403.97
1–189 21476.70  1.53 21478.33 L189
190–347 18013.41  1.60 18013.66
pLG72
Glu-C (1/5000) 1–146 17347.57  1.22 17948.66 E146
Subtilisin (1/2000) 1–150 17751.44  1.51 17751.11 T150
1–116 13643.55  0.99 13642.59 Y116
117–153 4454.52  1.00 4454.89
Trypsin (1/2000) 1–128 15110.15  1.49 15109.22 R128
129–153 2988.58  0.15 2988.28
Chymotrypsin
(1/2000)
1–61 7030.38  0.38 7030.08 W61
62–153 11066.37  0.73 11067.41
1–130 15908.85  1.12 15908.20 W130
135–153 2188.96  1.40 2189.34
hDAAO-pLG72 complex
Glu-C (1/2000) 1–336 38198.09  1.10 38198.39 E336
Subtilisin (1/10 000) 1–167 19237.07  0.82 19236.82 F167
168–347 20255.54.1.81 20255.16
1–180 20619.58  0.84 20619.31 N180
181–347 18872.35  0.64 18872.69
Trypsin (1/2000) 1–297 34004.15  1.51 34003.70 R297
298–347 5488.24  0.32 5488.28
Chymotrypsin
(1/2000)
1–35 3851.66  0.13 3851.62 Y35
36–347 35640.87  1.0 35640.35
1–55 6056.99  0.5 6057.07 Y55
56–347 33434.86  1.48 33434.90
1–296 33846.89  1.39 33847.51 L296
297–347 5644.50  0.43 5644.47
a Experimental mass value  standard deviation.
Table 1. Peptides generated by digestion
of hDAAO, pLG72, and hDAAO–pLG72
complex with different proteases and
identified by ESI-MS analysis after
fractionation by RP-HPLC.
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cross-link between hDAAO and pLG72 was identified,
as inferred by the triple-charged ions at 943.45 (corre-
sponding to the experimental MH+ value 2828.35)
interpreted as the hDAAO peptide 173–191 linked to
the pLG72 fragment 59–63 (theoretical MH+ value
2828.42 Da), besides several dead-end modifications
Fig. 1. Proteolysis of hDAAO. (A) Schematic representation of preferential proteolytic sites in hDAAO alone and in the presence of pLG72
(indicated by blue and purple bars, respectively). C = chymotrypsin; S = subtilisin; T = trypsin; G = endoprotease Glu-C; X = SB3 cross-link
(red bar). (B, C) Representation of the sites of proteolysis (spheres) within the three-dimensional structure of hDAAO homodimer (pdb code
2du8); colors as in panel A.
Fig. 2. Scheme of the strategy employed for the identification of the regions involved in hDAAO–pLG72 complex formation by means of
cross-linking based on BS3. Red arrow: gel-based approach showing the electrophoretic analysis of 12.5 lM hDAAO (lane 1), 62.5 lM pLG72
(lane 2), and the corresponding hDAAO–pLG72 complex (at 1 : 5 subunit molar ratio, lane 3) incubated for 15 min and then cross-linked by
adding 625 lM BS3. Lane 3 was also analyzed by western blot using anti-hDAAO (3A) and anti-pLG72 antibodies (3B): besides some protein
bands related to intramolecular cross-links occurring within both hDAAO and pLG72, immunodetection analyses revealed that the band at
~ 75 kDa (arrow) was positive to both antibodies. Blue arrows: in solution, gel-free procedure.
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(namely, the abortive modification of peptides occur-
ring when only one arm of the bifunctional cross-link-
ing agent reacts) and some internal cross-linkings both
in pLG72 and hDAAO. Figure 3 shows the fragmen-
tation spectrum where several ions of the y-ion and b-
ion series confirmed the identity of the hDAAO173–191
peptide. Fragmentation spectra of cross-linked pep-
tides often suffer from the fact that collisional activa-
tion energy typically favors the formation of product
ions from only one of the two constituent peptides
[31], generally the longer one. The double-charged ions
y12
2+, y13
2+, y14
2+, y15
2+, y16
2+, accounting for frag-
ments of the 173–191 hDAAO peptide cross-linked
with peptide 53–63 from pLG72, were considered to
be the key signals to confirm the linkage between the
two proteins through K62 pLG72 and T182 hDAAO.
It is worth noting that these cross-linked fragments are
doubly charged, as the presence of two connected pep-
tide moieties might suggest.
Model of pLG72 tertiary structure
As the experimental three-dimensional structure of
pLG72 has not been solved, a model of its tertiary
structure was built by homology modeling using the
I-TASSER server. Five potential models based on a
three-dimensional structure of templates belonging to
small a-helix proteins (e.g., T4 lysozyme) were pro-
duced. The reliability of the I-TASSER models was eval-
uated based on: (a) the position of the exposed
regions identified by limited proteolysis (in the
pLG72-VA model all cleavage sites are located in the
protein surface); (b) the position of the residue identi-
fied by cross-linking with hDAAO (notably, in the
pLG72-VA model, the residues K4, K36, K46, K62,
and L120 labeled by BS3 are all located on the pro-
tein surface and the side chains of M1 and K4 are
juxtaposed to yield the internal cross-link); (c) the
computational analysis of the quality of the models
by the SAVES metaserver. Indeed, the selected model
(pLG72-VA, Fig. 4A) shows an a-helix content of
~ 62%, which is in good agreement with the experi-
mental value obtained by CD analysis (~ 73%) [20].
pLG72-VA significantly differs from the model pro-
posed by [32,33]: the latter was built using 1zca as
template, a protein that shares a negligible sequence
identity with pLG72 (an overall identity of 10.3%
with a maximal identity of 27%, considering only
~ 30% of the template, and a blast E-value of 4.9).
Notably, in silico molecular docking analysis showed
that the pLG72-VA model binds chlorpromazine
(CPZ) (Fig. 4B), an aliphatic phenothiazine drug
known for its ability to interact with pLG72, forming
a complex possessing a predicted Kd ~ 11 lM (pre-
dicted binding energy: 6.6 kcalmol1) close to the
experimental value (~ 5 lM) [12,13]. CPZ is bound to
pLG72-VA by hydrophobic interactions only and
with the Cl atom solvent exposed; see Fig. 4B.
Furthermore, the availability of the pLG72 struc-
ture model and of the experimental structure of
hDAAO made it possible to predict their mode of
interaction by protein–protein molecular docking
using the server ZDOCK. As the residues K62
(pLG72) and T182 (hDAAO) were identified by
cross-linking experiments, only the complexes in
which these two residues were close to the contact
surfaces were considered by ZDOCK. Three alternative
hDAAO–pLG72 complexes were produced. The one
showing the highest agreement with limited proteoly-
sis analysis protection data (see Fig. 1 and Table 1)
and possessing the highest surface of contact
between the two proteins was considered for further
analysis (Fig. 4C,D). In the proposed mode of inter-
action, the distance between the -NH2 group of K62
of pLG72 and the OH-group of T182 of hDAAO is
12.2 A with a distance between the C-atom of the
corresponding residues of 17 A. These values are
within the experimentally observed distance con-
straint for the BS3 reagent (which has a linker arm
11.4 A long) that is 26–30 A between C-atom of the
linked residues [34].
From the calculation of the solvent-accessible sur-
face, the predicted hDAAO–pLG72 complex excludes
1038 A2 in hDAAO and 1072 A2 in pLG72 from sol-
vent contact, pointing to a stable interaction.
Design of C-terminal truncated forms of pLG72
Four truncated variants of pLG72 were designed by
in silico analyses. Analysis of full-length pLG72 by
employing PSIPRED software revealed a highly unstruc-
tured C-terminal region (Fig. 5A): in agreement with
MobiDB analysis (data not shown), the pLG721–123
variant was selected in order to obtain a more stable
recombinant protein lacking the disordered C-terminal
tail. With the same purpose, an even shorter protein
form was designed: pLG721–94. The latter variant lacks
the last 59 residues which are conserved in the prod-
ucts of isoforms 1–3 of G72 gene transcript
(GI:126362975, GI:240120173, GI:240120029, respec-
tively) [35], and eventually correspond to the form of
the human protein expressed in G72 transgenic mice,
reported as AFB69504.1 in the NCBI database
(GI:377551785) [36]. The protein corresponding to
pLG7272–153 is recognized as an interaction domain
with DAAO by the Pfam database (PF15199, http://
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Table 2. BS3-modified peptides. The measured precursor masses are included, along with the error of the measured precursor ion
compared to the theoretical mass. Peptide sequences are reported with the position within the protein and the flanking residues. Modified
residues are reported in bold, dead-end modified residues are underlined, cross-linked residues are connected by lines.
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pfam.xfam.org/): this observation suggests that it
could correspond to a structurally and functionally
stable domain. Finally, pLG721–64 has been designed
in response to results gathered from the experiments
of this work with the aim to identify the minimal
interacting N-terminal region excluding the overlap-
ping sequence between the variant pLG721–94 and
pLG7272–153, see Fig. 5B.
In order to investigate the role played by the C-
terminal tail, a synthetic peptide encompassing the
region from 122 to 153 was used to evaluate the bind-
ing and the inhibitory effect on hDAAO.
Properties of pLG72 deletion forms
The deletion variants of pLG72 were expressed in
E. coli using the pETM11 plasmid and the same con-
ditions previously used for the full-length protein [20].
Recombinant pLG72 variants largely accumulated as
inclusion bodies and were solubilized and refolded in
the presence of the anionic detergent NLS, reaching a
> 95% degree of purity and a yield of 155–525 mg
pure protein per liter fermentation broth.
The pLG72 variants showed absorbance spectra dif-
fering in wavelength of maximum intensity and in
Table 2. (Continued)
a The reported error is calculated as the difference between the experimental and the theoretical mass values in p.p.m.
Fig. 3. MS/MS spectra of the triply charged ions at m/z 943.45 (experimental [MH]+ m/z 2828.35, calculated [MH]+ m/z 2828.41) interpreted
as peptide 173–191 of hDAAO linked to peptide 59–63 of pLG72 (see inset). The product ions are indicated with the observed mass.
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extinction coefficient (Table 3). Indeed, different pro-
tein fluorescence spectra were recorded for the deletion
variants, depending on the number of Trp residues
(three for the full-length pLG72, two for the 1–123, 1–
94, and 72–153 variants, and one for the 1–64 variant)
and the microenvironment surrounding the aromatic
amino acid probe—in particular, compare the different
fluorescence yields of the three pLG72 proteins
Fig. 4. Homology model of pLG72 and proposed mode of interaction with CPZ and hDAAO. (A) Model of pLG72-VA, produced by I-TASSER
server using the structure of T4 lysozyme (pdb code 217l) as template; residue K62, identified by cross-linking experiments with hDAAO, is
represented in purple. (B) Mode of CPZ binding to pLG72-VA obtained by automated molecular docking simulations using AUTODOCK VINA [50];
the ligand is shown in van der Waals and sticks representation (white atoms), orientation of pLG72-VA is reversed in comparison with panel
A. The dark blue depicts the region deleted in pLG721–123, and light blue depicts the region deleted in pLG7272–153. Residues forming
noncovalent interactions with CPZ are shown as sticks. (C) Surface representation of pLG72-VA model: proteolytic sites are shown in
orange, dead-end modified residues by BS3 are shown in pink and cross-linked K62 residue is shown in purple. M1 and K4 form an
intramolecular cross-link (see Tables 1 and 2 for details). (D) Model of hDAAO–pLG72 complex as predicted by ZDOCK server; pLG72-VA is in
green, hDAAO monomers in violet and cyan. (E) Details of the H-bonds formed at the contact interface. Residues identified by cross-linking
experiments are shown in van der Waals radius representation, and residues forming H-bonds at the interface are shown as sticks; dotted
lines represent hydrogen bonds.
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containing two Trp residues (Fig. 6A). The fluores-
cence spectrum of polypeptide 122–153 showed a blue
shift (maximum at ~ 360 nm) and an intensity similar
to that of the longer pLG7272–153 variant, although it
contains a single Trp residue: this indicates that
W130 is a solvent exposed in the polypeptide corre-
sponding to the pLG72 C-terminal tail. Similarly, the
near-UV CD spectra of pLG72 deletion variants
resembled the one recorded for the full-length protein,
differing in intensity of the positive peaks at
~ 265 nm (Fig. 6B). A similar content of secondary
structure elements (mainly a-helices) for all the
pLG72 forms investigated was apparent by the far-
UV CD spectra, with the main exception of the 122–
153 polypeptide (Fig. 6C).
The thermal stability of the tertiary structure of
pLG72 was investigated following the CD signal at
265 nm. As compared to the full-length protein, the
lowest stability was apparent for the pLG721–94 vari-
ant and the highest Tm was observed for the shorter
variant 1–64 (showing a 15 °C increase in melting tem-
perature; Table 3).
When the oligomeric state was analyzed by size-
exclusion chromatography, the full-length pLG72
showed a main peak corresponding to a dimeric form of
the protein (KAV ~ 0.442, Mr = 43.8 kDa) and a minor
peak at high molecular mass (KAV ~ 0.009,
Mr ~ 740 kDa): their relative intensity was approximately
2.5 : 1.0 [12]. A similar elution profile was observed for all
deletion variants, the only exception being the pLG721–94:
in the latter case, the peak at high molecular mass was
absent and a new peak corresponding to a hexameric state
(KAV ~ 0.29, Mr = 117 kDa) was apparent (not shown).
For all pLG72 variants, DLS analysis of the main peak
eluted from size-exclusion chromatography indicated the
proteins were in a dimeric state.
pLG72 was reported to bind large, aromatic com-
pounds such as CPZ, a well-known drug used to
treat schizophrenia [14]. All deletion variants inter-
acted with CPZ with an affinity similar to the full-
length pLG72 (Table 3), in agreement with the struc-
tural model showing that it binds to a hydrophobic
pocket without forming specific noncovalent interac-
tions (Fig. 4B). The lowest affinity was observed for
pLG7272–153, which lacks a region involved in CPZ
binding in our model.
hDAAO binding to pLG72 variants
The interaction of full-length pLG72 to hDAAO gen-
erates a ~ 200 kDa complex formed by two hDAAO
homodimers and two pLG72 monomers (KAV ~ 0.195)
[12,13]. Size-exclusion chromatography of a mixture of
hDAAO and pLG72 proteins confirmed production of
the ~ 200-kDa complex for all deletion variants (not
shown). The interaction was then investigated by SPR
technology: hDAAO was immobilized on the chip sur-
face and all pLG72 variants were used as free analytes.
A low micromolar dissociation constant value for the
hDAAO–pLG72 variants complex was determined
(Table 3 and Fig. 7). These results show that deletion
of the C-terminal tail positively affects the interaction
with hDAAO; conversely, the lack of the N-terminal
region slightly negatively influences the hDAAO–
pLG72 interaction (resulting in a 1.4-fold weaker bind-
ing; Table 3). Interestingly, the 122–153 polypeptide
did bind aspecifically to hDAAO (Kd >> 10 lM,
Fig. 7).
Fig. 5. Deletion variants of pLG72. (A) Psipred analysis of
disordered regions in pLG72. Conf = confidence of prediction;
C = coil; E = strand; H = helix. (B) Schematic representation of the
pLG72 variants produced in this work.
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We previously demonstrated that the main effect of
pLG72 binding to hDAAO was a slow inactivation of
the flavoenzyme [12]. We now investigated the effect of
0.5-, 1-, 2-, and 4-fold molar excess of the different
pLG72 deletion variants on hDAAO activity after
30 min of incubation. At a 1 : 2 hDAAO:pLG72 ratio,
all the deletion variants inhibited the flavoenzyme to a
limited extent: 25–50% of inhibition versus > 80%
observed using the full-length pLG72 (Fig. 8). At a
four-fold pLG72 molar excess, the 1–64 and 1–94
shorter variants were significantly less effective
in inhibiting hDAAO than the pLG7272–153 (the
one showing the lowest affinity for hDAAO), the
pLG721–123, and the full-length protein. On the other
hand, the short polypeptide 122–153 did not affect
hDAAO activity at any molar ratio, supporting aspeci-
fic binding.
Discussion
Schizophrenia is a complex neurodevelopmental disor-
der [37] in which susceptibility genes are assumed to
play a specific role in the pathophysiology of the dis-
ease via abnormal synaptic connectivity [38]. Among
the proposed susceptibility genes [39–41], we have
focused in past years on the one involved in the cata-
bolism of the neuromodulator D-serine, a full agonist
at the glycine site of the NMDAR [42], namely,
DAAO and its interacting partner pLG72 [3]. The
human flavoenzyme DAAO was the object of a
plethora of investigations [12–15,20,27], while little is
known about the product of the primate-specific G72
gene [17,43]. pLG72 is a small protein (153 amino
acids) assumed to localize on the cytosolic side of the
outer mitochondrial membrane where it can interact
with neosynthesized hDAAO before it targets peroxi-
somes [14]. pLG72 was proposed as a ‘negative chap-
erone’ [44], i.e., a modulator of the protein
conformation that negatively affects enzyme activity,
as it promotes enzyme inactivation and degradation
[12–15].
In the absence of atomic resolution data, orthogonal
structural information is needed to accurately interpret
the findings; therefore, we employed low-resolution
Table 3. Comparison of properties of full-
length and deletion variants of pLG72.
pLG72
forms
(molecular
mass, Da)
Wavelength
of maximal
absorbance,
nm (e,
mM1cm1) Kd,CPZ (lM)a
Kd,hDAAO
(lM)a Tm (°C)
a
Molecular
mass by
LS (Da)a
1–153 (18 079) 268 (34.780) 1.56  0.21 2.6  0.4 59.2  2.7 35 075  315
1–123 (17 576) 268 (26.125) 0.82  0.27 0.40  0.05 66.3  11.0 33 818  461
1–94 (14 162) 265 (23.490) 0.95  0.29 2.1  0.3 50.9  4.6 28 307  56
72–153 (12 743) 263 (24.280) 2.33  0.33 3.7  0.1 64.6  1.2 24 815  175
1–64 (10 526) 259 (13.715) 1.02  0.28 2.2  0.2 73.7  1.4 20 707  82
a Mean  standard deviation, n = 3.
Fig. 6. Spectral properties of pLG72 variants. (A) Fluorescence spectra; (B) near-UV CD spectra; (C) far-UV CD spectra. Full-length pLG72
(black); pLG721–123 (blue); pLG721–94 (light blue); pLG7272–153 (red); pLG721–64 (green); pLG72122–153 (dotted black).
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techniques, such as those based on the coupling of
classical biochemical approaches (limited proteolysis
and chemical cross-linking) with mass spectrometric
techniques, to provide an overall characterization of
the surface topology of the hDAAO–pLG72 complex.
Controlled experimental conditions of limited proteol-
ysis produce specific cleavages on the exposed/flexible
regions of the protein which are identified by the mass
of the resulting complementary peptides. The evidence
that, in complex with pLG72, hDAAO shows a higher
sensitivity to proteolysis suggests that this interaction
decreases the overall compactness of the flavoenzyme,
supporting previous results [13]. This is a peculiar
observation as the opposite is often observed, i.e., a
decrease in the overall flexibility and accessibility of
individual proteins when they combine to form a com-
plex. Conformational changes occurred both within the
C-terminal tail, which became less flexible and exposed,
as well as at the N-terminal end of the flavoenzyme,
which was only cleavable in the presence of pLG72
(Fig. 1). Cross-linking experiments identified the single
covalent interaction between T182 in hDAAO and K62
in pLG72. Notably, K62 is in close proximity to the site
recognized by chymotrypsin in free pLG72 and thus
likely exposed on the protein surface. The information
gathered from both structural approaches were used to
select the mode of interaction between the known three-
dimensional structure of hDAAO and the pLG72 model
(predicted to be an a protein; see Fig. 4).
The reliability of the pLG72 tertiary structure
model is supported by its in silico ability to bind
CPZ in docking analyses and the experimental evi-
dence of decreased affinity for this aromatic ligand
in the pLG7272–153 variant lacking part of the resi-
dues contributing to the binding site (Table 3 and
Fig. 4B). In order to validate this model, four
Fig. 7. SPR experiments of the interaction of hDAAO (immobilized on the chip) with full-length pLG72 (A) and the variants pLG721–123 (B),
pLG721–94 (C), pLG721–64 (D), pLG7272–153 (E), and pLG72122–153 (F).
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deletion variants were produced. The three pLG72
variants lacking incremental regions at the C termi-
nus, as well as the form lacking the 71 N-terminal
residues, are dimeric in solution, contain secondary
and tertiary structures (Fig. 6), and interact with
hDAAO. As shown in Fig. 4E, specific residues of
pLG72 belonging to protein loops in the 1–92 region
seem to be explicitly involved in the interaction with
hDAAO: as a result, the strongest decrease in affin-
ity for hDAAO was apparent for the pLG7272–
153 N-terminally deleted form lacking K62 (i.e., of
the residue identified by cross-linking experiments).
According to the proposed protein interaction mode
reported in Fig. 4D, only the last three C-terminal
residues of pLG72 interact with hDAAO, thus
explaining the slight change in binding affinity
observed for the pLG72 C-terminal deletion variants.
Indeed, although the deletion of residues 65–153
results into the loss of a significant portion of inter-
face surface, the buried solvent-accessible area in the
pLG721–64 variant–hDAAO complex is only halved
in comparison to the full-length protein (i.e., 520
versus 1057 A2, respectively, as calculated by PDBE-
PISA) [45]. Furthermore, we cannot exclude a differ-
ent conformation of these shorter variants in
comparison with the wild-type pLG72. Deletion of
the C-terminal tail of pLG72 in the 1–123 variant,
the region with the highest degree of disorder
[46,47], results into a more stable protein (Tm is
7 °C higher) which binds to hDAAO with a higher
affinity (Kd is 0.4 lM) in comparison to the full-
length pLG72.
On the other hand, the hDAAO inhibitory capacity
of pLG72 variants is difficult to reconciliate with the
proposed pLG72 model and hDAAO interaction
mode. Actually, the lowest hDAAO inhibitory capac-
ity is apparent for the shorter N-terminal pLG72
forms (1–64 and 1–94), while the inhibitory efficacy of
pLG7272–153 was largely preserved (Fig. 8). Altogether,
the C-terminal half of pLG72 sequence seems to be
required to induce the alterations in hDAAO confor-
mation associated with loss of its catalytic function.
Further investigations such as cross-linking and limited
proteolysis experiments of the pLG721–64 and
pLG7272–153 with hDAAO will be required to refine/
validate the proposed pLG72 model.
Our results with the pLG72122–153 peptide differ
from the ones gathered by [35] that reported a stronger
interaction with hDAAO as compared to the full-length
pLG72: the latter result was based on a nonquantitative
pull-down experiment employing a biotinylated pLG72
form while our evidence arises from size-exclusion chro-
matography and SPR analyses on the unmodified pro-
tein. Indeed, the same authors reported an increase in
hDAAO activity at increasing pLG72 concentrations.
The main difference with our analyses was related to the
enzymatic assay that was performed without free flavin
adenine dinucleotide (FAD). The cofactor is absolutely
required in the assay mixture as FAD dissociation con-
stant is 8 lM for hDAAO [48]: in the absence of exoge-
nous FAD, large part of hDAAO is present in solution
in the apoprotein, inactive form and measurement of
the initial velocity assays the effect of pLG72 on the
apoprotein–holoenzyme equilibrium. As compared to
the wild-type counterpart, for the pLG72122–153 peptide,
a small, ~ 20% increase in hDAAO activity using 10 lM
pLG72 was reported by [35], a value resembling the one
we also observed (10–15%, Fig. 8): this result highlights
that pLG72122–153 binding does not affect hDAAO con-
formation.
From a pharmacological point of view, a decrease
in inhibitory hDAAO potency of class C compounds
(a novel class of inhibitors which act on the flavoen-
zyme via an allosteric, covalent mechanism) was
apparent in the presence of pLG72, consistent with
a model in which the hDAAO–pLG72 interface
shields the cysteine residues of the flavoenzyme from
this modification [44]. The same study identified
compounds that were more potent hDAAO inhibi-
tors (class A compounds) when pLG72 was present.
Elucidation at the structural level of the mode of
hDAAO–pLG72 interaction is quite exciting as it
opens up possibilities for designing novel molecules
that target the complex and can be more advanta-
geous therapeutically.
Fig. 8. Effect of increasing amounts of pLG72 on the activity of
hDAAO. The residual activity was assayed 30 min after incubation
of 13 lM hDAAO and pLG72 (at the indicated molar ratios), at
25 °C. The activity of hDAAO alone is referred as 100%. Full-
length pLG72 (black); pLG721–123 (blue); pLG721–94 (light blue);
pLG721–64 (green); pLG7272–153 (red); pLG72122–153 (gray).
n.d. = not determined. Bars represent mean  SD, n = 4.
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Experimental procedures
Cloning, expression, and purification of pLG72-
deleted variants
pLG72 variants were produced in E. coli using the
pETM11 expression vector (Novagene, Merck-Millipore,
Billerica, USA). In order to clone the G72 gene [20] in the
pETM11 plasmid, the NcoI restriction site present in the
sequence of G72 was removed by using the QuikChange kit
(Agilent Technologies, Santa Clara, CA, USA) and the fol-
lowing oligos: Fw: 50-CAGCGTAGCTTATGCCCTTGGG
TTTCGTATTTGCC-30; Rv: 50-GGCAAATACGAAACC-
CAAGGGCATAAGCTACGCTG-30. The resulting G72
gene, corresponding to full-length pLG72, was used as a tem-
plate for four different mutagenesis reactions, applying the
appropriate oligos designed to obtain 50- or 30-deleted pLG72
gene. The mutated DNA fragments were inserted into the
pETM11 plasmid using the NcoI and XhoI restriction sites,
yielding pLG72 variants containing an N-terminal 6x His tag.
All the deletion variants were expressed and purified by fol-
lowing the procedures reported in [20], with slight modifica-
tions. The concentration of the purified full-length and deleted
pLG72 variants was determined using the experimentally
determined extinction coefficient at ~ 270 nm (see Table 3).
For mass spectrometry analysis, the final protein preparations
were equilibrated in 20 mM sodium pyrophosphate buffer, pH
8.5, 150 mM NaCl, 5% glycerol, 1 mM dithiothreitol (DTT),
containing 0.06% N-lauroylsarcosine (NLS).
The synthetic peptide encompassing residues from 122 to
153 was purchased from Inbios S.r.l. (Naples, Italy).
DAAO preparation and activity assay
Recombinant hDAAO was expressed in E. coli and purified
as reported in [48]. For mass spectrometry analysis, the
final enzyme preparation was equilibrated in 20 mM sodium
pyrophosphate buffer, pH 8.5, 150 mM NaCl, 5% glycerol,
and 1 mM DTT, containing 40 lM FAD: the protein was
diluted in plain buffer without FAD before use. The con-
centration of the purified hDAAO was determined using
the extinction coefficient at 455 nm (12.2 mM1cm1) [48].
DAAO activity was assayed with an oxygen electrode at
pH 8.5, air saturation, and 25 °C, using 28 mM D-alanine
as substrate in the presence of 0.2 mM FAD.
Complementary proteolysis experiments
Enzymatic hydrolyses of hDAAO, pLG72, and the hDAAO–
pLG72 complex were performed at 37 °C in 20 mM sodium
pyrophosphate, pH 8.5, 150 mM NaCl, 5% glycerol, 0.06%
NLS, and 1 mM DTT, with either trypsin, chymotrypsin, sub-
tilisin, or Glu-C, and at enzyme-to-substrate ratios ranging
from 1 : 100 to 1 : 5000 (w/w). The time course of proteolysis
was monitored by sampling the reaction mixture at different
time intervals (from 1 to 30 min). The reaction was stopped
by adding 20% trifluoroacetic acid (TFA) or a denaturing
buffer (300 mM Tris/HCl, pH 8.0, 6 M guanidine, 10 mM
EDTA) and the incubation mixtures were separated by
reverse-phase (RP) HPLC on a Vydac C4 column
(250 9 4.6 mm, 300 A pore size) with a 10–65% acetonitrile
linear gradient in 0.1% TFA over 30 min, at a flow rate of
1 mLmin1. Elution was monitored at 220 nm and individual
fractions were collected and analyzed by ESI-MS on a ZQ sin-
gle quadrupole instrument (Waters-Micromass, Milford, MA,
USA). Protein solution was injected into the ion source at a
flow rate of 10 lLmin1. Data were elaborated using the
MASSLYNX program (Waters-Micromass). The multiply
charged ions of horse heart myoglobin (Sigma-Aldrich, St.
Louis, MO, USA, average molecular mass: 16951.5 Da) was
used to calibrate the instrument in a separate injection; all
masses are reported as average values: an average error of
about 50 p.p.m. was observed for the experimental masses in
respect to theoretical values.
Cross-linking experiments
Once the optimal protein-to-cross-linker molar ratio was
established in preliminary experiments, hDAAO–pLG72
complex cross-linking experiments were carried out on a
preparative scale: 3 nmol of hDAAO and 15 nmol of pLG72
were incubated at 37 °C for 15 min in 200 lL of 20 mM Na-
HEPES, pH 8.5, 150 mM NaCl, 0.06% NLS, and 1 mM DTT,
and then treated with a 50-fold molar excess of BS3, which con-
tains an amine-reactive N-hydroxysulfosuccinimide ester at
each end of an eight-carbon spacer arm, for 30 min at 25 °C;
the reactionwas stopped by addingTris to a final concentration
of 20 mM. The protein sample was desalted by RP-HPLC on a
Vydac C4 column with a 25–65% acetonitrile linear gradient in
0.1% TFA over 2 min, at a flow rate of 1 mLmin1. Elution
was monitored at 220 nm. Fractions were collected, analyzed
by LC-MS, and evaporated to dryness in a Speed Vac concen-
trator (Savant, Thermo Fisher Scientific, Waltham, MA,
USA), resuspended in 10 mM ammonium bicarbonate, pH 8.0,
digested with trypsin at 37 °C, enzyme-to-substrate ratio of
1 : 50 (w/w), overnight, and subjected to LC-MS/MS analysis.
Mass spectrometry and database search
LC-MS analysis was carried out on a ZQ system equipped
with a Z-SPRAY source and a quadrupole analyzer,
coupled to a 2690 Alliance HPLC using a Vydac C4 col-
umn (Waters-Micromass). The protein was eluted at a flow
rate of 0.5 mLmin1 with a 10–60% CH3CN gradient in
0.1% TFA for 1 min. Data were elaborated using the MASS-
LYNX program (Waters-Micromass).
LC-MS/MS analyses were carried out on a CHIP MS
6520 QTOF equipped with a capillary 1200 HPLC system
and a chip cube (Agilent Tech., Palo Alto, CA, USA). After
loading, the peptide mixture (8 lL in 0.1% formic acid) was
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first concentrated and washed at 4 lLmin1 in a 40-nL
enrichment column (Agilent Tech. chip), with 0.1% formic
acid in 2% acetonitrile as eluent. The sample was then frac-
tionated on a C18 reverse-phase capillary column
(75 lm 9 43 mm in the Agilent Tech. chip) at a flow rate of
400 nLmin1, with a linear gradient of eluent B (0.1% for-
mic acid in 95% acetonitrile) in A (0.1% formic acid in 2%
acetonitrile) from 7 to 60% for 50 min. Peptide analysis was
performed using data-dependent acquisition of one MS scan
(mass range from 400 to 2000 m/z) followed by MS/MS
scans of the three most abundant ions in each MS scan.
Preliminarily, raw data from nano LC-MS/MS analyses
were used to query nonredundant protein databases (Uni-
protSprot with taxonomy restriction to human), using in-
house MASCOT software (Matrix Science, Boston, MA, USA)
that established hDAAO and/or pLG72 as the principal
components of the samples. These searches were performed
with a parent mass tolerance of 20 p.p.m. and a fragment
tolerance of 0.6 Da. Carbamidomethyl cysteine was searched
as a constant modification. Variable modifications included
methionine oxidation and peptide N-terminal glutamine
cyclization to pyroglutamate. An average error of about
5 p.p.m. was observed for the experimental masses of linear
peptides in respect to theoretical values.
Putative cross-linked peptides were identified with the
open mass modification strategy developed by [30], using
PROTEIN PROSPECTOR version 5.6. Open mass modification
searches were performed against a restricted database con-
sisting of hDAAO and pLG72 only. In such cases, mass
modifications of any integer value between 138 (corre-
sponding to intramolecular cross-linking) and 4000 Da on
lysine, serine, and threonine residues or protein N termini
were added to further modify the variables.
For the gel-free strategy, the MS/MS ion search of the
human UniProt database by using the MASCOT software, with
carboxyamidomethylation of cysteine as fixed modification
and oxidation of methionine and pyro-Glu formation from
Gln at the N terminus of peptides as the only variable modi-
fications, assigned ions to linear peptides of both proteins
and then used the results to prepare a list of signals the mass
spectrometer should ignore for fragmentation in a subse-
quent run with the same sample. This procedure was used to
search for species in low abundance such as those originating
from cross-linked peptides. Raw data from the run with the
exclusion list were analyzed according to the open mass mod-
ification strategy developed by [30] with Batch-Tag, MS-
Bridge, and MS-Product tools within the PROTEIN PROSPECTOR
package. All putative cross-links were then verified by man-
ual inspection of the corresponding MS/MS spectrum.
Molecular modeling and design of pLG72
variants
The homology models of the pLG72 tertiary structure were
built using the I-TASSER server [49] and the 3D structure of T4
lysozyme as template (pdb code 217l, overall sequence iden-
tity 20.8%). Model quality was evaluated using the Structure
Analysis and Verification Server (SAVES, http://ser-
vices.mbi.ucla.edu/SAVES/) and, in particular, taking into
account results from the ERRAT algorithm [50]. A specific
residue was considered belonging to the protein surface when
its solvent-accessible surface was larger than 15 A2, as calcu-
lated using the PYMOL module findSurfaceResidues.
Molecular docking studies were performed by the AUTO-
DOCK VINA, a package based on an iterated local search glo-
bal algorithm [51]. The structure of the ligand CPZ was
designed and energy-minimized using AVOGADRO [52], and
the structure of pLG72 models produced by I-TASSER were
used for docking simulations. PYMOL software was used to
analyze docking results (www.pymol.org/).
Protein–protein docking simulations were performed
using the ZDOCK server [53], the pLG72-VA model, and the
experimental 3D structure of the hDAAO homodimer (pdb
code 2e4a). Results were filtered such that only complexes
having K62 (pLG72-VA) and T182 (hDAAO) in the inter-
acting regions were returned from the server. Secondary
structure composition was calculated with STRIDE [54].
Bioinformatics tools were used to design pLG72 vari-
ants; in particular, the secondary structure prediction server
psipred (http://bioinf.cs.ucl.ac.uk/psipred/); the protein data-
base BLASTP (http://blast.ncbi.nlm.nih.gov/blast/Blast); the
Pfam protein families database (http://pfam.xfam.org/); and
the MOBIDB 2.0, an improved database of intrinsically disor-
dered and mobile proteins (http://mobidb.bio.unipd.it).
Analytical methods for protein characterization
hDAAO and pLG72 proteins were detected by western blot
analysis using a rabbit anti-hDAAO polyclonal antibody
(Davids Biotechnologie, Regensburg, Germany) or a rabbit
anti-pLG72 polyclonal antibody (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA). A donkey anti-rabbit IgG anti-
body (Jackson ImmunoResearch, West Grove, PA, USA)
was used as a secondary antibody coupled to the ECL system
(GE Healthcare, Wauwatosa, WI, USA) for detection.
The oligomeric state of pLG72 proteins and interaction
with hDAAO were determined by using a SEC-LS sys-
tem consisting of a semipreparative size-exclusion
chromatography column (Superdex200 10/30; GE Health-
care) by means of an Akta chromatographic system (GE
Healthcare) coupled to a light-scattering detector (mini-
DAWN TREOS-Wyatt Technology Co., Santa Barbara,
CA, USA) and a differential refractive index detector (Sho-
dex RI-101). We collected, recorded, and processed the scat-
tering data with the ASTRA software (5.3.4.14 version; Wyatt
Technology). The following elution buffer was used: 20 mM
Tris/HCl, pH 8.5, 150 mM sodium chloride, 5% glycerol,
5 mM 2-mercaptoethanol, 40 lM FAD, and 0.06% NLS.
Absorbance spectra were recorded at 25 °C using a
Jasco 630 spectrophotometer (Jasco Europe, Cremella,
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Italy): extinction coefficients at ~ 270 nm for the pLG72
variants were obtained by denaturing the protein variants
in 20 mM Tris/HCl, pH 8.5, 100 mM NaCl, 5% glycerol,
5 mM 2-mercaptoethanol, 0.06% NLS, and 6 M urea, and
using the theoretical extinction coefficients calculated with
the protein parameter tool on the Expasy site (www.
expasy.org).
Protein fluorescence spectra were recorded on a Jasco
FP-750 spectrofluorimeter, using an excitation wavelength
of 280 nm at a 0.5-lM protein concentration and at
15 °C. CD spectra were recorded on a Jasco J-715 or J-
810 spectropolarimeter equipped with a Jasco PTC-343
Peltier thermostatic cell holder using a cell path length of
1 cm for measurements above 250 nm (0.4 mg pro-
teinmL1) and 0.1 cm for measurements in the 190- to
260-nm range, at 20 °C [55]. Thermal denaturation analy-
ses were conducted by following the CD signal at
265 nm by temperature ramp experiments in the 20–
100 °C range; the sample was heated at a rate of
0.5 °Cmin1. Spectra were recorded in 20 mM Tris/HCl
pH 8.5, 150 mM NaCl, and 5% glycerol.
Surface plasmon resonance analysis
Real-time binding assays were performed on a Biacore
3000 surface plasmon resonance (SPR) instrument (GE
Healthcare). Recombinant hDAAO (20 lgmL1) was
immobilized on a CM5 Biacore sensor chip (carboxymethy-
lated dextran surface) (GE Healthcare) in 10 mM sodium
acetate, pH 4.0, by using the EDC/NHS chemistry, to a
final density of ~ 7000 resonance units; a flow cell with no
immobilized protein was used as a control. Binding assays
were carried out by injecting 60 lL of different concentra-
tions of pLG72, pLG721–123, pLG721–94, pLG721–64,
pLG7272–153, and pLG72122–153 at 20 lLmin1, using
HBS-P20 (10 mM Hepes, pH 7.5, 0.1 M NaCl, 3 mM
EDTA, and 0.005% P20; GE Healthcare) as running buf-
fer. Each sensorgram was corrected for the response
obtained in the control flow cell and normalized to base-
line. BIAevaluation analysis package (version 4.1; GE
Healthcare) was used to subtract the signal of the reference
channel. As the rate of dissociation (koff) is at the limit of
the instrument record (< 1 E6 s1), the affinity constant
of the interaction was determined from the dependence of
maximal intensity of the response on analyte concentrations
(i.e., from the steady-state data and not from the kinetic
ones). The fit of the equilibrium values for the SPR
response (RUmax value) versus the ligand concentration
was performed using the GRAPHPAD PRISM v4.00 (San Diego,
CA, USA) and the one-site binding equation.
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